A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies
Time: 11:30 am
day: Conference Day 2
Details:
- PIT565 is a first-in-class, CD19xCD3xCD2, IgG-like, trispecific antibody that targets CD19+ cells and at the same time engages CD3 and CD2 (a costimulatory receptor) on T cells, which leads to redirected T-cell cytotoxicity toward CD19-positive malignant B cell
- Preclinical data demonstrate more robust anti-tumor response and overall T cell effector functions compared with the bispecific control
- PIT565 is currently in a Phase I, open-label study to characterize the safety and tolerability of PIT565 in patients with R/R B-NHL and R/R B-ALL to determine recommended dose(s), schedule(s), and route(s) of administration for future studies, as well as to estimate the preliminary antitumor activity of PIT565
